TeamDrive
RUS

NovaMedica

www.novamedica.com

NovaMedica is a modern Russian pharmaceutical company established in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceutical products and technologies as well as at development and implementation of own R&D-projects.

NovaMedica owns intellectual property rights within Russia and the CIS for 36 innovations which are part of the portfolio of RusnanoMedInvest, venture capital foundation. These are drugs for antivirus and anti-inflammatory therapy, to cure ophthalmic diseases and epilepsy as well as innovative technologies to detect oncological and infectious diseases.

NovaMedica also develops a pipeline of its own drug products. R&D Division of the company plans to develop about 15 own drugs by 2022. Five out of them are already on the different stage of development – from creation of a drug formulation up to clinical trials and state registration, and four more are on the stage of launch. These are drugs to cure disease in the sphere of gastroenterology, pain treatment, neurology, ophthalmology and rheumatology.

In April 2017 NovaMedica launched the Technology Center with state-of-the-art technological capabilities which were previously unobtainable in the Russian pharmaceutical industry.

In 2016 NovaMedica became the key partner of Pfizer in Russia. Within the frameworks of this partnership NovaMedica stared construction of a pharmaceutical GMP-facility in the Kaluga region in May 2017. 

NovaMedica possesses a well-developed infrastructure to market promotion and selling of pharmaceutical products. 

Media Center

  • 20 September 2017

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation. The Russians have been pressuring foreign pharmaceutical companies to engage in local production if they want to be in its market. Earlier this year, Russia-based NovaMedica announced it began work on a new plant in Russia’s Kaluga region where it will produce 30 of Pfizer’s sterile injected generic medications for the local market.

  • 19 September 2017

    Clinical trials of drugs for autoimmune diseases and cancer soon to start in Russia

    Clinical trials of about 30 new medicinal products for the treatment of cancer, autoimmune and hereditary diseases are expected to start in the Russian Federation. This was announced by the Russian Minister of Health Veronika Skvortsova at Biotechmed, a specialized conference.

  • 19 September 2017

    Kazakhstan plans a phased introduction of regulated prices for all drugs

    The Ministry of Health of the Republic of Kazakhstan elaborated a draft Law of the Republic of Kazakhstan “On Changes and Amendments to Certain Legislative Acts of the Republic of Kazakhstan on the Issues of Circulation of Medicines and Medical Devices” in order to improve the regulation in this area and create a patient-oriented drug provision model.

  • 18 September 2017

    Yakutia team aims to keep degenerative brain disease at bay

    Scientists at the North-Eastern Federal University in Yakutsk (NEFU), in Russia’s Far East, have developed a method of alleviating symptoms and slowing down the progression of spinocerebellar ataxia, or atrophy, an acute genetic brain disease that leads to dramatic motor coordination impairment and eventual shortening of a patient’s life expectancy. 

Read more